Skip to main content
Springer Nature Link
Account
Fig. 2 | Annals of Nuclear Medicine

Fig. 2

From: 18F-FDG PET/CT of off-target lymphoid organs in CD19-targeting chimeric antigen receptor T-cell therapy for relapsed or refractory diffuse large B-cell lymphoma

Fig. 2

Lymphoid organ metabolism and outcome of CAR-T-cell therapy. a Serial 18F-FDG PET/CT (upper row) showing metabolically active disease at baseline (PET1), partial remission at PET2, and progressive disease at PET3 (that is, unfavourable outcome). Marked early reduction of spleen activity, both in absolute quantification (SUVmean) and relative to liver metabolism (lower row). b Marked early reduction in activity of lymphoid organs was associated with worse outcome (spleen signal, P = 0.0368; lymph node signal, P = 0.0470). c Low bone marrow signal and low activity of lymphoid organs early after CAR-T-cell therapy demonstrated a borderline significant association with poor outcome (P ≤ 0.0784). d Metabolic activity of lymphoma burden was higher in patients developing neurotoxicity (P = 0.0489)

Back to article page